Year: 2025
Type: article
Abstract: Purpose. To evaluate the clinical efficacy of topical application of Emoxipi ne in patients with glaucoma. Material and methods. The article presents the results of a 6-month prospective observational study of topical application of Emoxypine 1% in 66 patients (132 eyes) with primary open-angle glaucoma of stage I–II and concomitant neurodegenerative changes in the organ of vision against the background of type 2 diabetes mellitus. Male — 17 (25.7%), female — 49 (74.3%), average age: 67.91±7.14 years. The main group consisted of 35 (70 eyes) patients who received 1% of Emoxypine instillation along with standard therapy; the control group consisted of 31 patients (62 eyes) who received standard therapy. Results. After 6 months, Emoxypine treatment in main group there was an increase of the thickness of the peripapillary layer of retinal nerve fibers in lower and upper sectors by 7.1% and 13%, an increase of thickness of the retinal ganglion cell layer in lower sector by an average of 7% according to optical coherence tomography data. In addition, there was an improvement in computer perimetry (decrease in the MD and PSD indices), as well as an increase in the overall antioxidant status of tears in comparison with the data of the control group. Conclusion. Emoxypine is an effective neuroprotective and antioxidant agent in the complex therapy of glaucoma and diabetic retinopathy, contributing to the stabilization of the glaucoma process and the preservation of visual functions. Clinical data obtained confirming the effectiveness of the drug as an adjuvant therapy for glaucoma to slow the progression of the disease. Keywords: glaucoma, emoxypine, antioxidant therapy, diabetic retinopathy
Source: POINT OF VIEW EAST – WEST
Authors: E.L. Usubov, G.M. Kazakbaeva, N.E. Shevchuk
Institutions: Bashkir State Medical University, Ufa Eye Research Institute
Language: English
Subfield: Ophthalmology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W7127086147